Clinical Trial Update: A Study in Type 1 Gaucher Patients to Evaluate the Pharmacokinetics, Safety and Pharmacodynamics of AT2101 [Phase 1]

View source ↗

Summary

A Phase 1 study evaluating the pharmacokinetics, safety, and pharmacodynamics of AT2101 in patients with Type 1 Gaucher disease has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 1 Gaucher Disease

Drugs mentioned

• AT2101

Snippet

Sponsor: Amicus Therapeutics | Conditions: Type 1 Gaucher Disease | Phase 1 | Status: TERMINATED